Biotechnology

Life science labs are eagerly exploring AI, but new data reveals a major roadblock: a fragmented digital landscape that keeps true innovation just out of reach.

Kardium’s landmark FDA win and a new wave of innovators signal a biotech boom, cementing British Columbia's status as a global hub for health innovation.

A new study of 100M insurance claims reveals a shocking failure: nearly 9 in 10 women in some states get no osteoporosis care after a fracture. Why?

Beyond amyloid plaques, a new therapy tackles Alzheimer's by reducing inflammation. Longeveron's latest data offers a glimpse into a regenerative future.

New real-time imaging gives surgeons a 3D molecular map of cancer in the OR, poised to end the emotional and physical toll of reoperations for many.

Takeda is deploying Boltz's frontier AI across its labs, betting that AI agents can accelerate medicine by acting as a creative partner for scientists.

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.

A quiet revolution is underway in animal feed, with enzymes driving a $4.6B market. This isn't just about cost; it's a tech-fueled shift to profitability.

Quoin Pharma is making a bold bet, building a full commercial operation in Japan for its rare disease drug years before a potential launch. Is this the new model?

Silo Pharma has navigated a critical headwind, regaining Nasdaq compliance. This move provides vital stability, allowing the firm to focus on its true test.

The appointment of Bethany Sensenig, a veteran of PE-backed turnarounds, signals CenExel is preparing for a major push to dominate the clinical research market.

Utah's Co-Diagnostics is transferring its AI-powered diagnostic platform to a Saudi JV. It's a bold move to crack a booming market and a critical test of its strategy.

A new partnership between Charles River and Lilly TuneLab merges AI with nonclinical testing, aiming to fast-track new medicines and level the field for biotechs.

A new grant from The Michael J. Fox Foundation highlights a radical approach to Parkinson's: targeting astrocytes to restore balance and halt neurodegeneration.

A new firm, Nortiva Bio, is launching with tech from MIT to turn daily pills into monthly doses, starting with a contraceptive backed by the Gates Foundation.

BioCardia bets its future on Japan's fast-track approval for its heart therapy, a strategic pivot that could unlock global markets or break the bank.

Companies like eGenesis are turning science fiction into reality with gene-edited pig organs. This is the story of a medical revolution at a crossroads.

With Hillary Aiken leading its new philanthropic arm, 23andMe Research Institute bets on private giving to accelerate its 'public good' DNA revolution.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

A court ruling clears the way for Curium's targeted cancer drug, promising new hope for patients and shaking up the multi-billion-dollar radiopharmaceutical market.